MedTrace Logo

DNA Methylation and Lung Disease in Cystic Fibrosis

NCT02884622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-06

No results posted yet for this study

Summary

Lung disease progression is variable among cystic fibrosis (CF) patients and depends on DNA mutations in the CFTR gene, polymorphic variations in disease-modifier genes and environmental exposure. The contribution of genetic factors has been extensively investigated, whereas the mechanism whereby environmental factors modulate the lung disease is unknown. Because these factors can affect the epigenome, investigators hypothesized that DNA methylation variations at disease-modifier genes modulate the lung function in CF patients.

Conditions

Interventions

OTHER

nasal epithelial

CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added

OTHER

Blood sampling

CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken

Sponsors & Collaborators

  • Vaincre la Mucoviscidose

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Raphaël CHIRON, MD · University Hospital, Montpellier

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-06-30
Completion
2016-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02884622 on ClinicalTrials.gov